Protocol Ledger

Therapeutic Cohort INF · ClinicalTrials.gov API v2

Infectious Disease and Vaccines: Phase II & III Clinical Trial Benchmarks

Protocol Ledger tracks 5,536 interventional Phase II and Phase III Infectious Disease and Vaccines protocols registered from 2018 through 2026, including 1,149 active studies, 2,510 completed studies, and 933 early-stopped studies (16.85% overall; 27.10% of closed trials).

Median Enrollment: 152.0 participants Median Completed Span: 456 days California Share: 832 studies (15.0%)

1. Reconciled Infectious Disease and Vaccines Execution & Stop-Cause Profile

Infectious Disease and Vaccines Cohort Metrics (Publication 47c4426df7e9d67d5bfe)
Clinical Trial Metric Verified Value Operational Context
Total Phase II & III Protocols (2018 to 2026) 5,536 Deterministic primary MeSH and condition-keyword assignment
Active Concurrent Pipeline 1,149 Recruiting, enrolling by invitation, and active follow-up protocols
Completed vs Prematurely Stopped 2,510 / 933 27.10% closed-trial attrition ratio across 3,443 closed protocols
Slow Accrual vs Safety & Futility Stops 228 / 99 / 61 Slow accrual (WS1) vs clinical safety (WS4) vs interim futility (WS5)
Physical Hospital Site Disclosure Rate 82.4% Named hospital campus participations vs anonymized CRO site slots

2. Leading Consolidated Trial Sponsors Focused on Infectious Disease and Vaccines

Consolidated Biopharma, Academic & Federal Sponsors (Infectious Disease and Vaccines Primary Focus)
Sponsor Hub Sector Protocols Active Completed FDA NDA/BLA
Sanofi Biopharma Industry 328 103 152 132
GSK Biopharma Industry 304 128 130 116
National Institute of Allergy and Infectious Diseases (NIAID) Federal / Public Agency 185 54 99 0
University of Oxford Academic / Institutional Sponsor 67 22 32 0
ModernaTX Biopharma Industry 62 14 42 0
McGill University Health Centre/Research Institute of the McGill University Health Centre Academic / Institutional Sponsor 35 13 7 0
London School of Hygiene and Tropical Medicine Academic / Institutional Sponsor 34 5 20 0
ANRS, Emerging Infectious Diseases Federal / Public Agency 32 13 7 0
ViiV Healthcare Biopharma Industry 30 11 16 0
Shionogi Biopharma Industry 29 9 15 8
Sinovac Biotech Co Biopharma Industry 27 12 15 0
Sorrento Therapeutics Biopharma Industry 27 0 3 0

3. Representative Multi-Center Phase II & III Infectious Disease and Vaccines Studies

Indexed ClinicalTrials.gov v2 Study Dossiers in Infectious Disease and Vaccines
NCT Study Protocol Brief Title Sponsor Phase Status
NCT05905172 Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis Beijing Continent Pharmaceutical Co Phase III RECRUITING
NCT06075745 Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates National Institute of Allergy and Infectious Diseases (NIAID) Phase II RECRUITING
NCT07512596 Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Nega Chia Tai Tianqing Pharmaceutical Group Co Phase II RECRUITING
NCT07184827 Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated rUTIs in Women TCM Biotech International Phase III RECRUITING
NCT06577558 Efficacy and Safety of SR1375 in Adult Patients With CAP Shanghai SIMR Biotechnology Co Phase II RECRUITING
NCT07388680 Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia Beijing Continent Pharmaceutical Co Phase II/III RECRUITING
NCT07157007 Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19 Traws Pharma Phase II RECRUITING
NCT07209761 A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis Otsuka Pharmaceutical Development & Commercialization Phase III RECRUITING
NCT05639647 Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections Pfizer Phase II RECRUITING
NCT05026749 Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children University of Alabama at Birmingham Phase III RECRUITING
NCT07722741 Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC Geneos Therapeutics Phase II RECRUITING
NCT06866405 A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose Pfizer Phase III RECRUITING
NCT06998043 Study With Phage for CF Subjects With Pseudomonas Lung Infection BiomX Phase II RECRUITING
NCT06631287 Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID Wes Ely Phase III RECRUITING
NCT05832229 Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase II RECRUITING
NCT06925321 A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections. Basilea Pharmaceutica Phase III RECRUITING

Related Therapeutic Condition Hubs & Crosswalks

Compare adjacent clinical cohorts: Oncology and Hematology · Rare Genetic, Women's Health, and Other · Neurology, Psychiatry, and Pain · Immunology, Rheumatology, and Dermatology, browse the interactive Hospital & Sponsor Directory, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI